Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AbbVie Inc (NYSE:ABBV)

102.49
Delayed Data
As of 4:00pm ET
 +2.15 / +2.14%
Today’s Change
59.27
Today|||52-Week Range
103.00
+5.98%
Year-to-Date
ABBV Regular Dividend: ABBV began trading ex-dividend on 01/11/18. A $0.71 dividend will be paid to shareholders of record as of 01/12/18.
Novartis (NVS) Announces Acceptance of Humira BLA by the FDA
9:11am / Zacks.com - Paid Partner Content
Galapagos Reports Topline Data From Osteoarthritis Study
Jan 08 / Zacks.com - Paid Partner Content
Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar
Jan 10 / Zacks.com - Paid Partner Content
Will J&J (JNJ) Continue to Tread Growth Path This Year?
Jan 05 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference i...
Jan 10 / Zacks.com - Paid Partner Content
Key Biosimilar Approvals in 2017: Progress Report
Jan 05 / Zacks.com - Paid Partner Content
AbbVie's Upadacitinib Gains Breakthrough Therapy Designation
Jan 09 / Zacks.com - Paid Partner Content
3 Large-Cap Pharma Stocks to Watch Out for This New Year
Jan 04 / Zacks.com - Paid Partner Content
4 Best Marijuana Stocks to Play the Green Rush
Jan 09 / Zacks.com - Paid Partner Content
Can AbbVie (ABBV) Stock Keep the Momentum Alive in 2018?
Jan 04 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close100.34
Today’s open100.26
Day’s range100.00 - 103.00
Volume8,528,643
Average volume (3 months)6,122,008
Market cap$160.0B
Data as of 4:00pm ET, 01/16/2018

Growth & Valuation

Earnings growth (last year)+15.97%
Earnings growth (this year)+15.15%
Earnings growth (next 5 years)+13.70%
Revenue growth (last year)+12.16%
P/E ratio24.9
Price/Sales3.98
Price/Book34.47

Competitors

 Today’s
change
Today’s
% change
SNYSanofi+0.13+0.29%
CELGCelgene-1.18-1.11%
GSKGlaxoSmithKline+0.42+1.12%
BMYBristol-Myers Squibb-2.89-4.60%
Data as of 4:15pm ET, 01/16/2018

Financials

Next reporting dateJanuary 26, 2018
EPS forecast (this quarter)$1.44
Annual revenue (last year)$25.6B
Annual profit (last year)$5.9B
Net profit margin23.10%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chairman &
Chief Executive Officer
Richard A. Gonzalez
Senior Vice President-
Operations
Azita Saleki-Gerhardt
Corporate headquarters
North Chicago, Illinois

Forecasts